alpha 1 antitrypsin

alpha 1 antitrypsin

A 54 kD glycoprotein that inhibits proteolytic enzymes (proteases),trypsin, chymotrypsin, elastases in lysosomes, plasmin, thrombin, collagenase, and others. Serum A1AT increases nonspecifically during inflammation and is a so-called acute phase reactant.
Elevated A1AT Inflammation, liver injury, increased oestrogen, pregnancy, malignancy, corticosteroid therapy.
Reduced A1AT Heterozygous A1AT deficiency, emphysema, prematurity, protein-losing disorders.
Ref range 2–4 g/L.
References in periodicals archive ?
Protein replacement therapy, involving weekly infusions of plasma-derived alpha 1 antitrypsin is approved but is only reimbursed in the United States and some European countries.
Contract notice: Provision of the drug alpha 1 antitrypsin (doe) for all osakidetza service organizations.
Active substance: Alpha 1 antitrypsin (doe) amount of active ingredient: 1 gr pharmaceutical form: Vial packaging conditions: Unit dose maximum price: 229 eur / vial of 1 gr (taxes not included).
Determination of alpha 1 antitrypsin phenotypes in plasma using isoelectric focusing on this agarose gel.
Alpha 1 proteinase inhibitor is intended for therapy of congenital alpha 1 antitrypsin deficiency, which leads to emphysema.
Alpha 1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for pi type Z.
Ongoing Phase II Trial Tests Ability to Deliver Sustainable Treatment in Patients with Alpha 1 Antitrypsin Deficiency (AAT) Using Proprietary AAV Technology
Stakeholder Opinions: Alpha 1 Antitrypsin Deficiency
com/reports/c83288) has announced the addition of Datamonitor's new report "Stakeholder Opinions: Alpha 1 Antitrypsin Deficiency" to their offering.
In addition to the ATryn(R) program, GTC is developing a recombinant human albumin, a recombinant human alpha 1 antitrypsin, a malaria vaccine, and a CD137 antibody to stimulate the immune system as a potential treatment for solid tumors.
Other recombinant human plasma proteins that GTC is developing include recombinant human albumin and recombinant human alpha 1 antitrypsin.
Nasdaq:INHL) announced today it has been issued US patent 5,993,783 on a method for delivering an inhaleable formulation of alpha 1 antitrypsin proteinase inhibitor.